| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.04 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.04 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | -0.087 | 0.05 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.076 | 0.05 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.094 | 0.05 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.06 | 0.05 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.06 | 0.05 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.1 | 0.05 |